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The promise of personalized medicine to deliver “the right treatments at the right time to the
right person” is the next frontier in healthcare. However, to implement personalized medicine in
chronic diseases such as diabetes mellitus and diabetic kidney disease (DKD), a number of differ-
ent aspects need to be taken into account. Better risk stratification and more precise options for
treatment need to be developed and included in clinical practice guidelines. A patient's unique
psychological, social and environmental situation also drive disease progression and outcomes.
Appraising the cost effectiveness of precision medicines is necessary, not just as the cost of
new therapies, but also the cost of diagnosis with novel methodologies and averted complica-
tions. As the prevalence of DKD grows worldwide to epidemic proportions, challenges such as
global disparities in resources, access to healthcare and prevalence need to be addressed. This
review considers these issues to achieve the short and longer-term goals of implementing per-
sonalized medicine in clinical practice.
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1 | INTRODUCTION
Diabetes mellitus, and especially type 2 diabetes, will be the seventh
leading cause of mortality by 2030.1 Diabetic kidney disease (DKD), a
complication of diabetes, is the most common cause of end-stage
renal disease (ESRD) both in the developed and the developing world
and accounts for 20% to 40% of patients starting renal replacement
therapy.2 Often diabetes and DKD are coupled with hypertension and
cardiovascular disease. Conventional treatment paradigms target risk
factors separately whereas comorbidities are not necessarily indepen-
dent of each other.
Over the last decades, there has been clear progress in assessing
risk factors and controlling diabetes. Subsequently, the prognosis of
patients with diabetes has gradually improved.1 Nonetheless, mortal-
ity, when compared to the general population, is higher, and the risk is
especially high in patients with impaired renal function. Many reasons
for the morbidity and mortality in DKD have been identified, including
suboptimal application of evidence-based therapies (eg, due to lack of
medication intensification by physicians or insufficient lifestyle
changes or medication adherence by patients), and variability in
response to medication (eg, inadequate efficacy of therapy even when
optimally applied, or genetic differences, leading to differential treat-
ment response). Additionally, a general lack of understanding of the
true pathobiology of DKD results in the treatment of symptoms and
diagnostic labels instead of a focus on causes and mechanisms. This
inefficiency results in many patients not being properly treated or not
receiving the maximum benefit possible for the multitude of treat-
ment modalities available. In order to improve the situation, a shift
towards care of the individual patient is needed, rather than for the
particular manifestation of the disease.
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Individualized medicine is a medical model that proposes the cus-
tomization of healthcare—with medical decisions, practices and/or
products being tailored to the individual patient. Ultimately, this medi-
cal model aims to improve patient care and achieve better outcomes,
all while providing a more cost effective healthcare system. Chronic
diseases like diabetes will cost the global economy $47 trillion over
the next 20 years. DKD additionally places a huge economic burden
on the healthcare system. The overall costs of care for people with
DKD are extraordinarily high, due in large part to the strong relation-
ship of DKD with cardiovascular disease and development of ESRD.3
The total annual cost to the National Health Service (NHS) in the
United Kingdom was £685 million ($1.5 billion),4 and the overall Medi-
care expenditures for diabetes and chronic kidney disease (CKD) in
the mostly older (≥65 years of age) US Medicare population were
approximately $25 billion in 2011.3 In view of these enormous costs
of DKD, identifying strategies for better cost-benefit is in the best
interest of patients and society.
In this article, we highlight different aspects that need to be taken
into account in order to individualize medicine in chronic diseases
including diabetes and DKD. Clinical practice guidelines need to
include stratifying risk more accurately and offer more precise treat-
ment options. The patient as an individual, with his or her unique
social and environment situations are also important drivers of disease
progression and outcomes. How to evaluate the cost effectiveness of
precision medicines is also necessary, but challenges in doing so are
present. Finally, the prevalence of DKD is growing worldwide, with
the fastest growth occurring in low-income countries (LIC) and low-
middle-income countries (LMIC). In order to implement personalized
medicine for DKD on a global scale, a number of challenges first need
to be addressed.
2 | NEED TO INCLUDE INDIVIDUALIZED
MEDICINE IN CLINICAL PRACTICE
GUIDELINES
For decades, DKD was considered a disease with a uniform clinical
course and pathophysiology. Evidence-based guidelines have been
developed based on findings obtained from large interventional trials,
and indeed these guidelines have been critical to improving the overall
quality of care of patients with DKD. Certainly, implementation of the
recommendations in clinical practice resulted in considerable progress
and benefit for the patients. However, growing consensus suggests
that renal disease in patients with diabetes is increasingly complex
and heterogeneous, and many patients do not follow the lowering
renal function/increasing albuminuria paradigm. Furthermore, recent
studies clearly show that the treatment response and risk of side
effects differ between individuals,5 and even within individuals over
time.6 These findings should modify our approach to DKD in general,
recognizing that the variability of the disease should be taken into
account when choosing therapy.
Currently, evidence for these guidelines is based on the effect of
drugs on clinical outcomes on populations included in clinical trials
rather than based on individuals. For example, in the TREAT study,
patients with DKD and anemia were randomly assigned to
darbepoetin alfa to achieve a hemoglobin level of 13 g/dL or to rescue
erythropoiesis stimulating agent (ESA) therapy in case hemoglobin
levels dropped to less than 9.0 g/dL. Active therapy did not reduce
the risk of either of the two primary composite outcomes (death or a
cardiovascular event or death or a renal event) but was associated
with an increased risk of stroke.7 These results were in line with sev-
eral other studies,8–10 and based on this evidence, the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) guideline group
recommended that in adult patients, ESAs must not be used to inten-
tionally increase hemoglobin above 13 g/dL (graded evidence level
1A).11 Interestingly in the “Normal Hematocrit Trial” by Besarab et al,
patients that actually reached the target hematocrit of 40% had by far
the lowest mortality of all participants.10 While this clearly could be
due to a selection bias, the question remains, what if in these individ-
uals, a normalization of hemoglobin could be superior to the guideline
recommended partial correction approach. This has never been tested
in a clinical trial and perhaps the full potential of ESAs is not exploited
in a certain subgroup of patients with anemia and CKD/DKD.
Individualization or at least stratification of therapy based on
patient characteristics is already part of some DKD guidelines. Meta-
bolic control should preferentially be achieved by drugs selected
based on the risk of associated hypoglycemia,12 and recent evidence
suggests that some agents, like SGLT2 inhibitors or GLP1 agonists
might even exert renal protection beyond their HbA1c lowering
capacity. Interestingly their efficacy to reduce specific renal endpoints
(eg, incidence of microalbuminuria) differs and thus in the future we
could see an even more targeted administration.13,14 However, addi-
tional efforts are necessary to maximize the risk-benefit ratio in other
areas of treatment of DKD. The recent guidelines of the American
Diabetes Association state that multiple-drug therapy is generally
required to achieve blood pressure targets. However, the combination
of an angiotensin converting enzyme (ACE) inhibitor and an angioten-
sin receptor blocker (ARB), and combinations of ACE inhibitors or
ARBs with direct renin inhibitors should not be used.15 This recom-
mendation is based on evidence that the risk of hyperkalaemia and/or
acute kidney injury is increased with these combinations when com-
pared to others.16 Nonetheless Palmer et al showed in the same
meta-analysis that double blockade of the renin-angiotensin-
aldosterone system is the most efficient way to lower proteinuria and
the risk of terminal end stage renal failure in patients with diabetes.16
Thus, if we could apply individualized medicine tools to identify the
population at highest risk of side effects, an optimal approach of
multiple-drug antihypertensive and albuminuria lowering therapy in
clinical practice could be individualized.
3 | IMPLEMENTING PERSONALIZED
MEDICINE: THE PATIENT'S PERSPECTIVE
Individualized medicine tries to incorporate all aspects of a person's
disease and response to treatment and identify the treatment that will
result in the optimal outcome for the individual patient. In order to
achieve this, individualized medicine focuses on an individual's unique
biological characteristics to tailor diagnostics and therapeutics to that
specific patient, by utilizing biological -omics techniques, that is,
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genomics, proteomics, metabolomics, epigenomics and pharmacoge-
nomics. In the past decade, a huge number of literature has been pub-
lished on various -omics techniques, focusing on among others,
mechanisms and pathways, biomarker discovery and better phenotyp-
ing. Indeed, systems biological approaches have led to the identifica-
tion of critical molecular abnormalities in DKD and have directly led to
development of new biomarkers and potential treatments for DKD.17
However, what is achieved in better clustering of patients is really just
precise risk stratification. Importantly, risk stratification does not
result in individualized medicine, but in more precise targeted medi-
cine, or more precise defining of subgroups. Better risk stratification
has been attempted in patients with diabetes, from risk engines like
United Kingdom Prospective Diabetes Study (UKPDS),18 to better
clustering of subgroups using sophisticated genotyping and bioinfor-
matics studies.19
Nevertheless as important as it is to identify the various patho-
physiology of DKD, other mechanisms in the person's life also play a
role in disease progression. Just as different biological pathways lead
to different types of renal disease in patients with diabetes, different
social and individual aspects can affect a person's disease progres-
sion.20 In order to go from precise individualized treatment to person-
alized treatment, another dimension needs to be added to the
plethora of biological -omics techniques. Taking in account an individ-
ual's personality, coping mechanisms, preferences, values, goals,
health beliefs, social support network, financial resources and unique
life circumstances—personomics—will also affect how and when a
given health condition will manifest in that person and how that con-
dition will respond to treatment.21 Not every patient has the same
values in life and people might make different choices in remarkably
similar situations. Importantly as well, the environment and society
the person is in, as well as the resources available, will also have
important roles in disease progression.
3.1 | A patient's viewpoint and concerns for
personalized medicine
Engaging patients and educating patients in order to advance per-
sonalized medicine is crucial. The clinical and research community
asks a lot from patients, namely time and accepting of risks in
exchange for hope of better treatment options and outcomes.
Patients often say that they want hope and value innovation and
exploration.22 Patients will and do give their time for research, with
full awareness that they may not personally benefit from it. From a
patient's perspective, there is often exciting news about new tech-
nology and the brave new world—but sometimes a yawning gap
between the media promise and real life with kidney disease. People
with renal disease are often enthused by the promise of a better life
with better treatments; however, awareness and understanding of
personalized medicine is variable.23 What people do want is person-
alized care that works for them as an individual and their individual
condition, whether it is more effective drugs or wearable technol-
ogy. However, translating research into clinical practice that actually
reaches the patient is very slow, and researchers need to mitigate
the balance between exploring current issues and difficulties of kid-
ney disease against the uncertain future. Studies on how to best
implement personalized therapy approaches should be prioritized in
order to shorten the time gap between discovery and exploration
studies and implementation.
There are many potential benefits for patients with personalized
medicine, and patients have clear goals. Personalized medicine can
have the ability to reduce the burden of disease, offer more conve-
nience for patients, can possibly buy time, and could lead to cost sav-
ings. For example, using personalized medicine to better identify the
right drug for the right patient can help minimize side effects. As
patients and family members must take time to attend medical
appointments, taking time off work or squeezing time away from their
personal obligations can become burdensome. Furthermore, personal-
ized medicine has the hope of earlier detection of disease and optimal
treatment, or making a kidney transplant last longer, which can all lead
to better outcomes and quality of life for patients and their families.
With the potential benefits of personal medicine come issues for
patients as well. Personal privacy may become an area of concern.
The genetic research and testing needed for personalized medicine
reveals information that patients may not want to know or be dis-
closed. Researchers and clinicians need to treat patients' data with
utmost care, and must be transparent on how data will be used to
avoid public loss of trust. Furthermore, retaining realism and honesty
on when and if personalized medicine tools will reach the patient, and
their affordability needs to be addressed. Stakeholders in personalized
medicine need to take a good look at patient-research priorities and
get better at explaining, following-up and valuing patient input.
4 | IMPLEMENTING PERSONALIZED
MEDICINE: THE PAYER'S PERSPECTIVE
Personalized medicine encompasses therapies targeted at patients
most likely to benefit. Providing these drugs requires regulatory
approval granting marketing authorization but also (for healthcare sys-
tems funded by tax-payers) evidence that these therapies work better
or as well as existing therapies, and reflect good value for money.
These health technology assessments (HTA) are performed by a deci-
sion body addressing paying for new therapies. For example, in
England, the National Institute of Health and Care Excellence (NICE)
serves this role for the NHS. Through its technology appraisal pro-
gram, NICE asks two questions of manufacturers of drugs, devices
and other health interventions: “how well does the new therapy work
compared with what the NHS already offers?” and “do the costs of
the new therapy reflect good value?” The NHS recognizes that,
because it uses limited resources, it must provide care that brings the
greatest benefit to the most people.
Often before a drug receives marketing authorization, and always
before appraisal, HTA defines the decision problem, that is, the popu-
lation, intervention (the technology of interest), comparator(s) (stan-
dard care) and outcomes. Ideally, for personalized medicine, the
population will be limited to subgroup of people most likely to benefit.
In estimating clinical effectiveness, HTA does not use outcome mea-
sures clinicians’ use in everyday care; for example, HTA would not
attempt to compare the value of improving glomerular filtration with
improving forced vital capacity. Appreciating that the same money
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cannot—at the same time—be spent on both, generic measures of
effectiveness common to all diseases are used, such as the quality-
adjusted life year. Therapy is deemed “effective” if it makes people
live longer and/or better. In calculating costs, the technology's price,
but also the costs of administering it, its adverse effects, and any
downstream complications are taken into account. For example, an
appraisal of a drug that delays dialysis would account for the price of
treatment, but also the cost of dialysis.
Appraising precision medicines includes challenges. Drugs offered
to people most likely to benefit are also more likely to be clinically and
cost-effective. Yet, defining these patients from clinical trial data
after-the-fact may not provide enough patients to find a drug's true
effect, and may generate chance (incorrect) findings. Clinical trial
strategies are evolving to identify which patients will benefit from the
drug and who will have unwanted side effects. For example, the Study
Of Diabetic Nephropathy With Atrasentan (SONAR) study
(NCT01858532) uses an enrichment strategy with companion bio-
markers to identify patients who respond favorably and unfavorably
to the study medication. SONAR was initiated to characterize the
long-term renal effects of atrasentan 0.75 mg/day in patients with
type 2 diabetes and nephropathy on top of standard care with an
ACEi or ARB, plus diuretic therapy.24,25 Eligible patients proceed to a
6-week enrichment period, after which patients with a response in
albuminuria (>30% reduction) and without unacceptable rise in body
weight (<3 kg) or B-type natriuretic peptide (<300 pg/mL) are ran-
domly assigned to long-term treatment with atrasentan or placebo, on
top of ACEi or ARB, plus diuretic therapy. However, false positive
findings may occur because subgroups are based on the biggest
observed effects. Appraisals must include the costs of diagnosing
patients with novel methodologies and companion diagnostics that
are required in personalized medicine (ie, various -omics techniques).
Setting prices and reimbursing for companion diagnostics need to be
addressed. Different countries will have different appraisal methods
and pricing and reimbursement policies.
5 | IMPLEMENTING PERSONALIZED
MEDICINE: THE GLOBAL PERSPECTIVE
Implementation of personalized medicine on a global scale includes a
number of challenges, opportunities and current realities in clinical and
research communities. There are huge variations in genetics, preva-
lence, rates of progression and outcomes in different regions of the
world. Differences in socioeconomic status, and access to care also
add to the challenges. There is an increasing appreciation that the
interaction of genes and environment needs to be studied in the con-
text of multiple genes and multiple environments, over time and space,
in order to better understand these variabilities, and then address them
to improve kidney health. The Global Burden of Disease and the Inter-
national Society of Nephrology (ISN) Global Kidney Health Atlas, offer
some insights into the impact of CKD on various populations. The lat-
ter describes the state of kidney care according to the six dimensions
of Universal Health Coverage, using robust survey methodology, and
capturing data from 125 countries, representing 93% of the world's
population. The global distribution of nephrologists is described as
8.83 per 1.87 million population, with huge disparities between LIC,
LMIC, upper-middle-income countries (UMIC) and high-income coun-
tries (HIC). In a number of regions, no aspect of kidney care is funded,
and registries are lacking for most kidney diseases or conditions
throughout the world. Basic testing for urine and blood with reliable
laboratory systems is not available in all locations, and the capacity for
the conduct of longitudinal cohort studies, with bio-sample banking, or
clinical trials is disproportionately available to HIC, than LIC, with huge
affected populations. Thus, the variation in access to care, research
and knowledge translation currently limits the global community's abil-
ity to reap the rewards offered from personalized medicine.
The requirements and needs for personalized medicine include
standardized clinical and hospital data systems. In addition, there is
need to address ethical, social and legal issues associated with discover-
ies which may impact specific populations, or individuals, and to identify
and contain costs related to data generated from molecular and genetic
probing and drugs developed. In addition it will be important to address
knowledge gaps of health care providers and patients about molecular
genetics and biochemistry, interpretation of test results, and the rele-
vance of information to treatment and prevention, so that the promise
that personalized medicine (improved clinical outcomes, lower costs by
managing existing diseases, increased therapeutic selection and medical
adherence) can be achieved. In the longer term, earlier detection, cura-
tive interventions and reduction in disease burden, are promised.
In order to move forward with personalized medicine on a global
scale, strategies to overcome challenges need to be identified. Defining
new methods of conducting trials, collecting and storing specimens and
sharing data is imperative in order to actualize the potential of personal-
ized medicine in ways to reach patients. There are numerous complex
interactions required to actualize the value of personalized medicine, and
the need to manage expectations of patients, clinicians, clinical trialists,
regulators, pharma development and funders. There are an increasing
number of international consortia of networks which include patients,
researchers and policy makers in different roles, so that we may begin to
address some of the issues limiting our ability to move forward: the ISN
is supporting the International Network of CKD (iNET CKD) cohorts, the
ISN-Advancing Clinical Trials (ISN-ACT) is working to leverage existing
infrastructures within ISN, and the European Association for the Study
of Diabetes (EASD) European Diabetes Forum aims to address the full
landscape of diabetes research and clinical care. Institutions such as the
George Global Health Clinical Institute, and consortia such as Nephrotic
Syndrome Study Network (NEPTUNE), Kidney Precision Medicine Pro-
ject (KPMP) and Biomarker Enterprise to Attack Diabetic Kidney Disease
(BEAt-DKD) are all working on aspects of personalized medicine in kid-
ney and/or diabetes. Additionally, the American Diabetes Association
has given special focus to personalized medicine.26 Through collabora-
tions, sharing of biosamples, databases, common protocols and multicen-
ter trials conducted worldwide, an improved understanding of diseases
affecting populations will be realized.
6 | CONCLUSIONS
In this article, we highlighted different aspects for implementing per-
sonalized medicine in diabetes and CKD (Figure 1). Stratifying risk
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more accurately and more precise options for treatment need to be
included into clinical practice guidelines. Treating the patient as an
individual, with his or her own unique social and environment situa-
tions, is of great importance. The societal and environmental setting
need to be considered, as culture, resources, access to healthcare and
prevalence differ greatly around the globe. Appraising the cost effec-
tiveness of precision medicines is necessary, as just the cost of new
therapies but also the cost of diagnosis with novel methodologies and
complications account. Implementing personalized medicine must
incorporate all these aspects.
Healthcare delivery systems in their current form are economically
unsustainable, given that healthcare consumes between 4% and 17% of
the gross domestic product in Organisation for Economic Co-operation
and Development (OECD) countries.27 The infinite demand for care in
aging populations, and finite clinical and financial resources, and an
increasing high cost of chronic diseases are all drivers of this unsustain-
ability. The promise of personalized medicine is that with deep pheno-
typing integrated with molecular profiles and clinical data on disease
patterns, we will in the short term, improve clinical outcomes, control
costs by managing existing diseases, enhance therapeutic selection and
increase medical adherence. In the longer term, earlier detection, cura-
tive interventions and reduction in disease burden, are promised. In
reality, personalized medicine has yet to show clinical, economic and
social value, and the benefits and aspiration of personalized medicine
have led to the recognizing of the complex reality of what we need to
achieve the short- and longer-term goals. Personalized medicine in
diabetes and DKD is an ambitious goal, but this should not preclude
aiming to bring patients the correct therapeutic strategies.
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FIGURE 1 Implementing personalized medicine includes suitable therapy options for a single patient's-specific illness and stage (co-morbidities),
using appropriate diagnostic tools and tailoring therapy to the patient's individual circumstances including underlying biology of the disease,
environmental, social and personal factors (indicated by the green circles in the figure)
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